/stocks — the workspaceLOADING
All RDGLSEC filings, by type → · Earnings date & implied move · Search inside filings
VIVOS INC (RDGL) is a surgical & medical instruments & apparatus company. Piotroski F-Score 2/8. 5 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
What’s behind RDGL’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
FY ending 2025-12-31 vs 2024-12-31.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from RDGL’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on RDGL plus an auto-SWOT — built from RDGL's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate RDGL using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
Projected from RDGL's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentRDGL files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
No lawmaker has disclosed a trade in RDGL under the STOCK Act.
The fair-value line is RDGL’s own median P/E, P/S, P/B and P/FCF applied to each year’s fundamentals — the price its typical valuation would have implied. Where the solid line sits above the dashed one, the stock traded at a premium to its own history that year; below, a discount. This is a description of past valuation, computed from RDGL’s filings and price history — not a forecast and not investment advice. A stock can trade above or below its own median for years.
Total return including reinvested dividends, from RDGL’s adjusted closing prices. Past return is not a forecast and not investment advice.
No tracked institution reported a position in RDGL in the latest 13F round.
| Korenko Michael KCEO AND PRESIDENT | BUY | $8K | view → |
| Weeks Brad AllanPresident | BUY | $3K | view → |
| Weeks Brad AllanPresident | BUY | $5K | view → |
| Korenko Michael KCEO AND PRESIDENT | BUY | $11K | view → |
| Weeks Brad AllanPresident | BUY | $5K | view → |
| Korenko Michael KCEO AND PRESIDENT | BUY | $9K | view → |
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.